GOLD guidelines recommend triple therapy with ICS/LABA/LAMA for patients who have dyspnea or exercise tolerance despite dual therapy with LABA/LAMA. A 2018 meta-analysis by Cazzola and colleagues had shown that the ICS/LABA/LAMA combination was superior for reducing the risk for COPD exacerbation and improving forced expiratory volume compared with LABA/LAMA combination therapy.
A fixed-dose ICS/LABA/LAMA combination inhaler is available, per López-Campos and colleagues. Triple therapy can also be administered by using the three drugs separately in three inhalation devices or combining ICS/LABA with a LAMA or LABA/LAMA with ICS in two inhalation devices.
According to Ferguson and colleagues, a subanalysis of the ETHOS trial demonstrated the benefits of a triple fixed-dose ICS/LABA/LAMA combination extended to patients with moderate as well as severe COPD.
Learn more about triple therapy for the maintenance of COPD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Chronic Obstructive Pulmonary Disease Maintenance Therapy - Medscape - Jul 22, 2022.